TY - JOUR
T1 - Long-Term Implantable, Flexible, and Transparent Neural Interface Based on Ag/Au Core–Shell Nanowires
AU - Araki, Teppei
AU - Yoshida, Fumiaki
AU - Uemura, Takafumi
AU - Noda, Yuki
AU - Yoshimoto, Shusuke
AU - Kaiju, Taro
AU - Suzuki, Takafumi
AU - Hamanaka, Hiroki
AU - Baba, Kousuke
AU - Hayakawa, Hideki
AU - Yabumoto, Taiki
AU - Mochizuki, Hideki
AU - Kobayashi, Shingo
AU - Tanaka, Masaru
AU - Hirata, Masayuki
AU - Sekitani, Tsuyoshi
N1 - Funding Information:
This work was financially supported by the Brain Mapping by Integrated Neurotechnologies for Disease Studies project of the Japan Agency for Medical Research and Development, grant from the Commissioned Research of NICT, and grants received from the Center of Innovation Program from the Japan Science and Technology Agency (JST). In addition, this work was partially supported by JST ERATO, JSPS KAKENHI, and JST PRESTO. The authors thank Showa Denko and JX Nippon Mining & Metals for their helpful discussions during fabrication of the proposed AgNW/Au interface, and extend their gratitude to following collaborators for useful discussions, equipment applications, and assistance during data acquisition— Prof. K. Suganuma and Prof. M. Nogi from the Institute of Scientific and Industrial Research (ISIR), and T. Oka, A. Yagura, Y. Harada, Y. Kasai, N. Kurihira, and members of the Comprehensive Analysis Center at ISIR. T.A. and F.Y. are co-first authors. T.A., T.U., Y.N., S.Y., M.T., and T.Se. designed, fabricated, and characterized the neural interfaces. F.Y., T.K., T.Su., H.Ham., K.B., H.Hay., T.Y., H.M., and M.H. designed and performed animal care, animal experiments, and characterizations from the medical viewpoint. All practices and operations performed on the animals in this study were approved by the Osaka University Animal Experimentation Committee, and the same were in accordance with Animal Research guidelines of the Osaka University.
Funding Information:
This work was financially supported by the Brain Mapping by Integrated Neurotechnologies for Disease Studies project of the Japan Agency for Medical Research and Development, grant from the Commissioned Research of NICT, and grants received from the Center of Innovation Program from the Japan Science and Technology Agency (JST). In addition, this work was partially supported by JST ERATO, JSPS KAKENHI, and JST PRESTO. The authors thank Showa Denko and JX Nippon Mining & Metals for their helpful discussions during fabrication of the proposed AgNW/Au interface, and extend their gratitude to following collaborators for useful discussions, equipment applications, and assistance during data acquisition?Prof. K. Suganuma and Prof. M. Nogi from the Institute of Scientific and Industrial Research (ISIR), and T. Oka, A. Yagura, Y. Harada, Y. Kasai, N. Kurihira, and members of the Comprehensive Analysis Center at ISIR. T.A. and F.Y. are co-first authors. T.A., T.U., Y.N., S.Y., M.T., and T.Se. designed, fabricated, and characterized the neural interfaces. F.Y., T.K., T.Su., H.Ham., K.B., H.Hay., T.Y., H.M., and M.H. designed and performed animal care, animal experiments, and characterizations from the medical viewpoint. All practices and operations performed on the animals in this study were approved by the Osaka University Animal Experimentation Committee, and the same were in accordance with Animal Research guidelines of the Osaka University.
Publisher Copyright:
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2019/5/23
Y1 - 2019/5/23
N2 - Neural interfaces enabling light transmittance rely on optogenetics to control and monitor specific neural activity, thereby facilitating deeper understanding of intractable diseases. This study reports the material strategy underlying an optogenetic neural interface comprising stretchable and transparent conductive tracks and capable of demonstrating high biocompatibility after long-term (5-month) implantation. Ag/Au core–shell nanowires contribute toward improving track performance in terms of stretchability (<60% strain), transparency (<83%), and electrical resistance (15 Ω sq−1). The neural interface integrated with gel-coated exterior microelectrodes preserves low impedance (1.1–3.2 Ω cm2) in a saline solution over the evaluated 5-month period. Besides the use of efficient conductive materials, surface treatment using antithrombogenic polymer tends to prevent the growth of granulation tissue, thereby facilitating clear monitoring of electrocorticograms (ECoG) in a rodent during chronic implantation. The flexible and transparent neural interface pathologically exhibits noncytotoxicity and low inflammatory response while efficiently recording evoked ECoG in a nonhuman primate via optogenetic stimulation. The proposed highly reliable interface can be employed in multifaceted approaches for translational research based on chronic implants.
AB - Neural interfaces enabling light transmittance rely on optogenetics to control and monitor specific neural activity, thereby facilitating deeper understanding of intractable diseases. This study reports the material strategy underlying an optogenetic neural interface comprising stretchable and transparent conductive tracks and capable of demonstrating high biocompatibility after long-term (5-month) implantation. Ag/Au core–shell nanowires contribute toward improving track performance in terms of stretchability (<60% strain), transparency (<83%), and electrical resistance (15 Ω sq−1). The neural interface integrated with gel-coated exterior microelectrodes preserves low impedance (1.1–3.2 Ω cm2) in a saline solution over the evaluated 5-month period. Besides the use of efficient conductive materials, surface treatment using antithrombogenic polymer tends to prevent the growth of granulation tissue, thereby facilitating clear monitoring of electrocorticograms (ECoG) in a rodent during chronic implantation. The flexible and transparent neural interface pathologically exhibits noncytotoxicity and low inflammatory response while efficiently recording evoked ECoG in a nonhuman primate via optogenetic stimulation. The proposed highly reliable interface can be employed in multifaceted approaches for translational research based on chronic implants.
UR - http://www.scopus.com/inward/record.url?scp=85063881948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063881948&partnerID=8YFLogxK
U2 - 10.1002/adhm.201900130
DO - 10.1002/adhm.201900130
M3 - Article
C2 - 30946540
AN - SCOPUS:85063881948
SN - 2192-2640
VL - 8
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
IS - 10
M1 - 1900130
ER -